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Abstract
Background: There is limited knowledge about mortality risk in persons with
increased haemoglobin A1c (HbA1c) levels below the diabetes threshold. Moreover,
little is known about how associations between increased HbA1c and mortality
depend on the length of follow-up. Therefore, we studied associations between
HbA1c and mortality over long-term follow-up in persons with and without known
diabetes.
Methods: We used data from two German population-based cohort studies: KORA
S4 Study (Southern Germany, n = 1458, baseline visits in 1999 to 2001, baseline age
55 to 74 years, mortality follow-up 16.8 years) and Heinz Nixdorf Recall (HNR) Study
(Ruhr area, n = 4613, baseline visits in 2000 to 2003, baseline age 45 to 75 years,
mortality follow-up 17.8 years). Adjusted log-linear models were fitted to estimate
relative risks (RRs) with 95% confidence intervals (CI).
Results: In both cohorts, participants with HbA1c 39 to 41 mmol/mol (5.7%-5.9%)
and HbA1c 42 to 46 mmol/mol (6.0% to 6.4%) did not have a larger overall mortality
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risk than participants with HbA1c < 39 mmol/mol (5.7%): the corresponding adjusted
RRs were 1.00 (95% CI: 0.83-1.21) and 1.01 (0.80-1.27) in KORA and 0.99
(0.82-1.21) and 0.83 (0.65-1.07) in the HNR Study. For the pooled cohorts, the RR
for HbA1c 39 to 46 mmol/mol (5.7%-6.4%) was 0.96 (0.85-1.07). Associations
between newly detected diabetes (HbA1c ≥ 6.5%) and mortality were weak after
4 and 8 years of follow-up, but were stronger after 12 years of follow-up, whereas
associations between previously known diabetes (baseline) and mortality decreased.
Conclusions: HbA1c-defined pre-diabetes is not associated with overall mortality. For newly
detected and previously known diabetes, mortality risks vary with length of follow-up.
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1 | INTRODUCTION
Both the WHO and the American Diabetes Association (ADA)
accepted HbA1c ≥ 6.5% to define diabetes.
1,2 Thus, HbA1c is now
established as an appropriate diagnostic test for diabetes. However,
international organisations have not agreed upon uniform HbA1c-
based definitions of pre-diabetes: the ADA recommends 39 to
46 mmol/mol (5.7%-6.4%), the International Expert Committee 42 to
46 mmol/mol (6.0%-6.4%), whereas WHO currently does not endorse
HbA1c as a criterion for defining pre-diabetes.
3
Studies on the association between HbA1c and all-cause mortality
have often focussed on persons with diabetes, and a J-shaped pattern
was observed with slight increases of mortality risk for very low
HbA1c values.
4 In the present study, we also took non-diabetic per-
sons into account, and we studied associations between HbA1c and
mortality using the novel cut-offs for HbA1c-defined diabetes and
pre-diabetes. We mainly addressed two research questions.
First, the mortality risk of persons with intermediate hyper-
glycaemia has extensively been studied for glucose-based pre-diabe-
tes, but less for increased HbA1c without diabetes. In a recently
published meta-analysis on the association between pre-diabetes and
all-cause mortality, the authors found that persons with impaired
fasting glucose (IFG) (ADA) and IFG (WHO) both had a slightly
increased risk of overall mortality [relative risk (RR) = 1.13 (95% confi-
dence interval (CI): 1.02-1.25 and RR = 1.13 (1.05-1.21), respec-
tively].5 However, for HbA1c 39 to 41 mmol/mol (5.7%-5.9%),
mortality risk estimated from four pooled studies was not increased
[RR = 0.97 (0.88-1.07)].5 In addition, for HbA1c 42 to 46 mmol/mol
(6.0%-6.4%) the meta-analysis included only one study showing an
increased mortality risk [RR = 1.21 (0.95-1.26)].6 However, the latter
study referred to a specific population of persons with normal glucose
tolerance and high diabetes risk. More recently, in two studies, the
mortality risk for HbA1c 42 to 46 mmol/mol (6.0%-6.4%) was investi-
gated in general populations, yielding inconsistent results.7,8
Second, the role of length of follow-up has hardly been taken into
account in studies on HbA1c and mortality, and little is known about the
impact of lengthof follow-upon the associations betweenHbA1c andmortal-
ity. Usually, studieswith various follow-up times are pooled inmeta-analyses.
Thus, our aim was to examine the association between intermedi-
ate hyperglycaemia defined by HbA1c and overall and cardiovascular
mortality using data from two population-based German cohort stud-
ies [KORA S4 Study, Heinz Nixdorf Recall (HNR) Study]. Additionally,
we right-censored the data after varying intervals of follow-up to
study the influence of length of follow-up on HbA1c mortality
associations.
2 | METHODS
2.1 | Study participants
The KORA S4 Study is a population-based prospective cohort study in
the region of Augsburg in Southern Germany. Baseline visits took
place in 1999 to 2001, and mortality was followed up to 16.8 years.
From 1653 KORA participants, persons with diabetes other than type
2 diabetes, unclear diabetes diagnosis or missing covariates were
excluded leaving a sample of 1458 participants (51.9% men, aged
55-74 years).
The HNR Study is a population-based prospective cohort study in
the Ruhr area in Western Germany. Baseline visits took place in 2000
to 2003, and mortality was followed up to 17.8 years. From 4814
HNR Study participants, persons with diabetes other than type 2 dia-
betes, or missing values for covariates were excluded leaving 4613
participants (49.5% men, aged 45-75 years). Study designs are
described in more detail elsewhere.9,10
Both studies were approved by the relevant institutional ethics
committees [the Bavarian Chamber of Physicians (KORA) and the
Ethics Committee of the Medical Faculty of the University Clinic
Essen (Recall)]. All participants gave their written informed consent.
2.2 | Variables
In both studies, for measurement of HbA1c, immune turbidimetric
assays were used: Tina-quant, Roche Diagnostics, Germany; Hitachi
717 Analyser in KORA S4, and ADVIA 1650, Bayer Diagnostics, in the
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Recall Study. In KORA, previously known diabetes was defined as
self-reports validated by questioning the responsible physician, or as
current use of glucose-lowering agents. In the HNR Study, previously
known diabetes was defined if participants gave a self-report of physi-
cian´s diagnosis, or if glucose-lowering drugs were taken. The follow-
ing HbA1c categories were used: previously known diabetes with
HbA1c ≥ 53 mmol/mol (7.0%) and HbA1c <53 mmol/mol; no previ-
ously known diabetes with HbA1c ≥ 48 mmol/mol (6.5%), HbA1c 42 to
46 mmol/mol (6.0%-6.4%), HbA1c 39 to 41 mmol/mol (5.7%-5.9%)
and HbA1c <39 mmol/mol (5.7%) (reference).
For further details on assessment of covariates, diabetes and pre-
diabetes, see References 9 and 10.
2.3 | Statistical analyses
For the binary responses ‘mortality’ and ‘cardiovascular mortality’, log-
linear models with a Poisson working likelihood and robust standard
errors were fitted, to estimate RRs with 95% CIs adjusted for age, sex,
body mass index, smoking, hypertension, physical activity, educational
years, total cholesterol, high-density lipoprotein cholesterol and his-
tory of cardiovascular diseases. To additionally account for the time
until death, we fitted an adjusted accelerated failure time (AFT) model
for interval-censored data with a Weibull distribution assumed for the
event times. The expected time until death for the pre-diabetes cate-
gories is the expected time until death for people with HbA1c <5.7%
multiplied by eß (ß = regression coefficient). For the pooled dataset,
we additionally fitted a proportional hazards Cox model.
Using the pooled data, we estimated RRs with 95% CI not only for
the total follow-up, but we also right-censored the data, and estimated
RRs with 95% CI for the first 4, 8 and 12 years of the follow-up period.
In an additional analysis on the association between HbA1c levels
and all-cause mortality, we only included study participants without
previously known diabetes (N = 5604, pooled data set), and we used
subcategories for HbA1c < 5.7%. The following categories were used:
≤4.6%, 4.7% to 4.8%, 4.9% to 5.1%, 5.2% to 5.4%, 5.5% to 5.7%, 5.8%
to 6.0%, 6.1% to 6.4% and ≥6.5%. The cut-offs 4.8%, 5.1%, 5.4%,
5.7% and 6.0% refer to the 10th, 25th, 50th, 75th and 90th percen-
tiles. The two deciles at the extreme ends were subdivided further.
As 195 and 201 individuals, respectively, were excluded because
of missing values, we also used multiple imputation with fully condi-
tional specification, for the analyses of the association between HbA1c
and overall mortality.
Analyses were performed with SAS (version 9.4; SAS Institute,
Cary, North Carolina).
3 | RESULTS
Overall, KORA participants were about 5 years older than HNR Study
participants and had higher values of HbA1c at baseline (Table 1). Of
1458 participants of the KORA S4 Study, 566 (38.8%) had HbA1c
values in the range of 39 to 46 mmol/mol (5.7%-6.4%) at baseline.
Among 4613 participants of the HNR Study, 907 (19.7%) had HbA1c
values in this range. Newly detected or previously known diabetes
was found in 162 (11.1%) KORA participants and 522 (11.3%) HNR
Study population.
KORA participants displayed a higher mortality rate than the
HNR Study population (20.7 vs 11.2 per 1000 person-years). How-
ever, the mortality rate of the latter increased to 18.9 per
1000 person-years when the analysis was confined to the same age
range and length of mortality follow-up of KORA.
In both cohorts, people with HbA1c 39 to 41 mmol/mol (5.7%-
5.9%) and HbA1c 42 to 46 mmol/mol (6.0%-6.4%) did not have a
larger overall mortality risk than participants with HbA1c <39 mmol/
mol (5.7%); the corresponding adjusted RRs were 1.00 (95% CI:
0.83-1.21) and 1.01 (0.80-1.27) in KORA and 0.99 (0.82-1.21) and
0.83 (0.65-1.07) in the HNR Study (Table 2). There were only small
differences in progression to death in persons with HbA1c 39 to
41 mmol/mol (5.7%-5.9%) and HbA1c 42 to 46 mmol/mol (6.0%-
6.4%) compared with HA1c <39 mmol/mol (5.7%; AFT models;
Table 2). In participants with newly detected, HbA1c-defined diabetes,
the overall mortality risk was slightly increased [RR = 1.15 (0.81-1.64)
in KORA and 1.27 (1.00-1.61) in the HNR Study].
For cardiovascular mortality, RRs were 0.96 (0.66-1.38) for HbA1c
39 to 41 mmol/mol (5.7%-5.9%) and 1.09 (0.71-1.65) for HbA1c 42 to
46 mmol/mol (6.0%-6.4%) in KORA, and the corresponding RRs were
TABLE 1 Baseline characteristics of the study groups: the HNR
and the KORA S4 Studies
HNR Study KORA
N 4613 1458
Age (y) 59.6 ± 7.8 64.1 ± 5.5
Sex [males (%)] 49.5 51.9
Years of education (ISCED) 14.0 ± 2.4 10.7 ± 2.4
BMI (kg/m2) 27.9 ± 4.6 28.7 ± 4.4
HbA1c (mmol/mol) 37 ± 9 40 ± 9
HbA1c (%) 5.5 ± 0.8 5.8 ± 0.8
Systolic blood pressure (mm Hg) 133.1 ± 20.9 136.2 ± 20.3
Diastolic blood pressure (mm Hg) 81.5 ± 10.9 80.3 ± 10.5
Hypertension (%) 56.0 56.7
Total cholesterol (mg/dL) 229.1 ± 39.2 242.7 ± 42.1
HDL cholesterol (mg/dL) 57.9 ± 17.1 57.5 ± 16.3
Smoking (%) Current 23.3 13.4
Former 34.5 39.0
Never 42.2 47.5
History of stroke (%) 2.8 2.9
History of myocardial infarction (%) 4.8 4.5
Follow-up time (y) 15.0 ± 3.4 14.1 ± 3.6
Note: Values are expressed as mean ± SD, median (first quartile, third
quartile) or proportion (%).
Abbreviations: BMI, body mass index; HDL, high-density lipoprotein; HNR,
Heinz-Nixdorf Recall; HbA1c, haemoglobin A1c; ISCED, International Stan-
dard Classification for Education.
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1.17 (0.76-1.80) and 1.14 (0.70-1.85) in the HNR Study (Table 3). For
the pooled data set, RRs were 1.01 (0.77-1.34), 1.10 (0.80-1.52), 1.32
(0.85-2.04), 1.89 (1.38-2.58) and 2.49 (1.78-3.49) for HbA1c 5.7% to
5.9%, 6.0% to 6.4%, ≥6.5%, known diabetes with HbA1c < 7.0%, and
for known diabetes with HbA1c ≥ 7.0% (reference HbA1c < 5.7%).
When both datasets were pooled, the following RRs were obtained
for people without previously known diabetes: 0.98 (0.86-1.13) for
HbA1c 39 to 41 mmol/mol (5.7%-5.9%); 0.91 (0.77-1.08) for HbA1c
42 to 46 mmol/mol (6.0%-6.4%); 1.23 (1.01-1.51) for Hb1c
≥48 mmol/L (6.5%; Table 4). For HbA1c 39 to 46 mmol/mol
(5.7%-6.4%), the RR was 0.96 (0.85-1.07). When HbA1c <39 mmol/mol
(5.7%) was split into HbA1c <31 mmol/mol (5.0%) and HbA1c 31 to
38 mmol/mol (5.0%-5.6%) with the latter subcategory as reference,
RRs were 0.98 (0.86-1.13) for HbA1c 39 to 41 mmol/mol (5.7%-5.9%)
and 0.91 (0.76-1.08) for HbA1c 42 to 46 mmol/mol (6.0%-6.4%).
For the pooled dataset, results of a proportional hazards Cox
regression agreed with the results of the Poisson and of the AFT
model for the association between HbA1c and all-cause mortality. The
hazard ratios with 95% CI were 0.95 (0.80-1.12), 0.91 (0.74-1.11),
1.29 (1.00-1.68), 1.69 (1.36-2.09) and 1.78 (1.40-2.27) for HbA1c
5.7% to 5.9%, 6.0% to 6.4%, ≥6.5%, known diabetes with
HbA1c < 7.0%, and for known diabetes with HbA1c ≥ 7.0% respec-
tively (reference HbA1c < 5.7%).
When the data were right-censored after 4, 8 and 12 years of
follow-up, two trends were observed (Table 4): first, associations
between diabetes newly detected at baseline and mortality were
weak after 4 and 8 years of follow-up [RR = 0.73 (0.32-1.67), and
1.11 (0.74-1.67) respectively], but became stronger after 12-year
follow-up [RR = 1.32 (1.04-1.69)]. Second, associations between dia-
betes known before baseline and mortality slightly decreased over
follow-up (Table 4).
After splitting HbA1c into subcategories, we observed a J-shaped
pattern with an indication for an increased all-cause mortality for
Hb1Ac ≤ 4.6% [adjusted RR = 1.25 (95% CI: 0.88-1.79), reference
HbA1c 4.9%-5.1%] (cf. Figure 1).
Using multiple imputation with fully conditional specification,
results for the association between HbA1c and overall mortality chan-
ged slightly: For the Recall Cohort, RRs for HbA1c 5.7% to 5.9%, 6.0%
to 6.4%, ≥ 6.5%, known diabetes with HbA1c < 7.0%, and for known
diabetes with HbA1c ≥ 7.0% were 1.01 (0.84-1.23), 0.86 (0.67-1.09),
1.29 (1.02-1.63), 1.43 (1.17-1.75) and 1.44 (1.15-1.81), respectively. For
the KORA cohort, the corresponding RRs were 0.98 (0.82-1.18), 0.96
(0.77-1.21), 1.07 (0.76-1.52), 1.47 (1.14-1.88) and 1.74 (1.32-2.31).
4 | DISCUSSION
This study found that increased HbA1c values 39 to 41 mmol/mol
(5.7%-5.9%) and HbA1c 42 to 46 mmol/mol (6.0%-6.4%) in people
without diabetes were barely associated with overall mortality in two
TABLE 2 Mortality rates and adjusted relative risks for overall mortality by HbA1c at baseline: the KORA S4 and the Heinz Nixdorf Recall
Study
Previously known
diabetesa HbA1c [mmol/mol (%)] N Deaths n (%)
Mortality rate per 1000




No <39 (5.7) 730 187 (25.6%) 17.8 (15.4-20.6) 1 1
No 39–41 (5.7-5.9) 369 99 (26.8%) 18.8 (15.3-22.9) 1.00 (0.83-1.21) 1.02 (0.89-1.16)
No 42–46 (6.0-6.4) 197 56 (28.4%) 20.5 (15.5-26.6) 1.01 (0.80-1.27) 0.94 (0.79-1.10)
No ≥48 (≥6.5) 43 18 (41.9%) 31.0 (18.4-48.9) 1.15 (0.81-1.64) 0.91 (0.69-1.19)
Yes <53 (<7.0) 65 34 (52.3%) 42.0 (29.1-58.7) 1.62 (1.28-2.04) 0.67 (0.55-0.82)
Yes ≥53 (≥7.0) 54 31 (57.4%) 48.9 (33.3-69.5) 1.93 (1.47-2.55) 0.60 (0.48-0.74)
All 1458 425 (29.2%) 20.7 (18.8-22.8) … …
Heinz Nixdorf Recall Study
No <39 (5.7) 3184 453 (14.2%) 9.4 (8.5-10.3) 1 1
No 39–41 (5.7-5.9) 554 93 (16.8%) 11.2 (9.1-13.8) 0.99 (0.82-1.21) 1.04 (0.88-1.23)
No 42–46 (6.0-6.4) 353 56 (15.9%) 10.5 (7.9-13.6) 0.83 (0.65-1.07) 1.22 (0.98-1.51)
No ≥48 (≥6.5) 174 46 (26.4%) 18.3 (13.4-24.4) 1.27 (1.00-1.61) 0.80 (0.63-1.01)
Yes <53 (<7.0) 197 70 (35.5%) 26.7 (20.9-33.8) 1.45 (1.18-1.77) 0.69 (0.57-0.85)
Yes ≥53 (≥7.0) 151 53 (35.1%) 26.3 (19.7-34.4) 1.36 (1.07-1.73) 0.75 (0.59-0.94)
All 4613 771 (16.7%) 11.2 (10.4-12.0) … …
Abbreviations: AFT, accelerated failure time; CI, confidence interval; HbA1c, haemoglobin A1c; RR, relative risk.
aPreviously known diabetes includes self-report of physician's diagnosis or intake of glucose-lowering drugs (ATC code A10)
bFor results of the pooled data, compare with Table 4 (right column).
cAdjusted for age, sex, body mass index, smoking, hypertension, physical activity, educational years, total cholesterol, high-density lipoprotein cholesterol
and history of cardiovascular diseases.
dFor example, in the KORA Study, for previously known diabetes with Hb1Ac < 53 mmol/mol, exp(beta) = 0.67 means: the expected time until death for
this category is the expected time until death for the reference category (no previously known diabetes, HbA1c < 39 mmol/mol) multiplied by 0.67.
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population-based cohort studies with long follow-up periods. More-
over, our study gives evidence that associations between HbA1c and
mortality vary over long follow-up periods: in persons with diabetes
newly detected at baseline, the mortality risk increased over follow-
up, whereas it slightly decreased in persons with diabetes previously
known at baseline. Furthermore, our study confirms earlier results
showing increased all-cause mortality in persons without diabetes
with very low HbA1c values.
4 In the pooled data set, there was an indi-
cation that cardiovascular mortality was slightly increased in persons
with HbA1c 42-46 mmol/mol (6.0%-6.4%); however, this effect esti-
mate was rather imprecise.
So far, results from the few studies on HbA1c in the pre-diabetes
range and overall mortality were inconsistent. In a large cohort study
using Health Survey for England data, HbA1c 39-46 mmol/mol was
not associated with increased mortality [HR = 0.95 (0.84-1.08)].11
From the ARIC Study (US), contradicting results were reported when
HbA1c 39 to 46 mmol/mol (5.7%-6.4%) was compared with
HbA1c < 39 mmol/mol (5.7%): with participants from visits 2 and 4, a
strong association was found for the fully adjusted model [HR = 1.31
(1.21-1.43)].8 However, in a recent analysis with older ARIC partici-
pants from visit 5 (age 66-90), barely any association was found
between HbA1c in the pre-diabetic range [39-46 mmol/mol (5.7%-
6.4%)] and total and cardiovascular mortality, respectively [HR = 1.03
(0.85-1.23), and HR = 1.00 (0.70-1.43)].12 Some studies indicated that
the mortality risk increases for HbA1c <31 mmol/mol.
13 However, the
choice of the reference category does not explain our results: when
we split HbA1c <39 mmol/mol (5.7%) and used HbA1c 31 to 38 mmol/
mol (5.0%-5.6%) as reference, this had very little impact on our results.
Our results have strong implications for the identification of high-
risk populations for diabetes prevention.2 Both glucose- and HbA1c-
based criteria have been proposed to be equally suitable to select
high-risk individuals for diabetes prevention.2 Moreover, combining
glucose-based criteria with HbA1c was shown to improve identifica-
tion of persons with higher risk of CVD.14 The optimal choice of the
screening method depends on the long-term goal of a prevention pro-
gramme. With respect to mortality, using HbA1c criteria alone may
miss high-risk individuals who should receive preventive interven-
tions. In various other studies, pre-diabetes defined by fasting glucose
demonstrated associations with long-term mortality.5 These findings
contribute to the recommendations regarding definitions of high-risk
individuals for diabetes prevention programmes.15
To our knowledge, the influence of length of follow-up on the
association between HbA1c and mortality has not been considered in
earlier studies. In the present study, the RR for overall mortality
among persons with diabetes newly detected at baseline was weak in
the first years of follow-up and increased with longer follow-up. This
is plausible because mortality may not yet increase strongly in the
very first years after diabetes onset. In older adults of the ARIC Study,
TABLE 3 Rates of cardiovascular mortality and adjusted relative risks for cardiovascular mortality by HbA1c at baseline: the KORA S4 and the
Heinz Nixdorf Recall Study
Previously known
diabetesa HbA1c (mmol/mol (%)) N Deaths n (%)
Mortality rate per 1000




No <39 (5.7) 728 72 (9.9%) 6.9 (5.4-8.7) 1 1
No 39–41 (5.7-5.9) 367 36 (9.8%) 6.9 (4.8-9.5) 0.96 (0.66-1.38) 1.03 (0.84-1.27)
No 42–46 (6.0-6.4) 197 23 (11.7%) 8.4 (5.3-12.6) 1.09 (0.71-1.65) 0.91 (0.71-1.16)
No ≥48 (≥6.5) 42 8 (19.1%) 13.9 (6.0-27.4) 1.37 (0.69-2.72) 0.82 (0.56-1.20)
Yes <53 (<7.0) 65 20 (30.8%) 24.7 (15.1-38.2) 2.35 (1.55-3.57) 0.56 (0.43-0.73)
Yes ≥53 (≥7.0) 54 18 (33.3%) 28.4 (16.8-44.9) 2.89 (1.80-4.63) 0.51 (0.38-0.68)
All 1453d 177 (12.2%) 8.6 (7.4-10.0) … …
Heinz Nixdorf Recall Study
No <39 (5.7) 3184 104 (3.3%) 2.2 (1.8-2.6) 1 1
No 39–41 (5.7-5.9) 554 25 (4.5%) 3.0 (2.0-4.5) 1.17 (0.76-1.80) 0.91 (0.63-1.33)
No 42-46 (6.0-6.4) 353 18 (5.1%) 3.4 (2.0-5.3) 1.14 (0.70-1.85) 0.94 (0.61-1.45)
No ≥48 (≥6.5) 174 11 (6.3%) 4.4 (2.2-7.8) 1.29 (0.72-2.30) 0.78 (0.46-1.34)
Yes <53 (<7.0) 197 20 (10.2%) 7.6 (4.7-11.8) 1.59 (1.00-2.51) 0.60 (0.39-0.92)
Yes ≥53 (≥7.0) 151 19 (12.6%) 9.4 (5.7-14.7) 2.18 (1.36-3.50) 0.47 (0.30-0.74)
All 4613 197 (4.3%) 2.9 (2.5-3.3) … …
Note: For the results of the pooled data, see Section 3.
Abbreviations: AFT, accelerated failure time; CI, confidence interval; HbA1c, haemoglobin A1c; RR, relative risk.
aPreviously known diabetes includes self-report of physician's diagnosis or intake of glucose-lowering drugs (ATC code A10).
bAdjusted for age, sex, body mass index, smoking, hypertension, physical activity, educational years, total cholesterol, high-density lipoprotein cholesterol.
cFor example, in the KORA Study, for previously known diabetes with Hb1Ac < 53 mmol/mol, exp(beta) = 0.82 means: the expected time until cardiovascular
death for this category is the expected time until death for the reference category (no previously known diabetes, HbA1c < 39 mmol/mol) multiplied by 0.82
dFor five individuals, there was no information on cause of death.
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for example, overall mortality was much larger in long-standing diabe-
tes (≥ 10 years) than in short-term diabetes.12 In persons with diabe-
tes previously known at baseline our observation that RRs decreased
with longer follow-up may be explained with increasing age during
long follow-up periods. In earlier studies, it was shown that hazards
ratios for the association between diabetes and mortality decrease
with old age.16,17 Using data from the Swedish National Diabetes Reg-
ister, for example, it was shown that the corresponding hazards ratios
decreased from 2.18 (2.02-2.34) in persons younger than 55 years to
1.02 (1.01-1.03) in persons older than 75 years.17
Strengths of our study are the use of data from two independent
cohort studies, and the long mortality follow-up of 17 years. Our
study has several limitations. First, the number of deaths was rather
small. Second, different devices were used to measure HbA1c in the
two cohort studies. However, both assays were traceable to the
NGSP (National Glucose Standardization Program) reference system,
and, therefore, they were well comparable. Third, results may not be
generalizable to the younger age, and may not apply to non-Cauca-
sians. Fourth, despite adjustment for multiple confounders we cannot
exclude residual confounding.
To conclude, HbA1c may not be a good predictor of mortality for
persons with intermediate hyperglycaemia. Additionally, the length of
follow-up periods should receive more attention in future studies.
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F IGURE 1 HbA1c and overall mortality in persons without
previously known diabetes. HbA1c, haemoglobin A1c
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